The FDA has approved a new non-opioid prescription medication, Journavx for adults with moderate to severe acute pain.

The FDA's approval of the non-addictive painkiller Journavx last week marked a milestone in the field of pain management. Why ...

a non-opioid painkiller that is the first novel pain drug to win government authorization in more than 20 years. Vertex Pharmaceuticals, which makes the drug, has billed it as an effective ...

The first shot taken at Medicaid, likely UnitedHealthcare coverage for Vertex's pain drug, and Optum’s wellness visit ad.

Some you might hold only temporarily, while others you own for decades. David Jagielski (Eli Lilly): A forever stock you can ...

The Massachusetts-based biotech plans to use the funds to push its candidates into mid-stage clinical trials in a space ...

The U.S. Food and Drug Administration has approved a novel prescription pain medication that targets sodium channels involved ...

Precision medicine is revolutionizing healthcare, and these genomic stocks are leading the way. Therefore, as this sector ...

The opioid epidemic continues to affect hundreds of thousands of people, but there may be hope for the future with a new, non ...

For the first time in more than 25 years, the U.S. Food and Drug Administration has signed off on a new type of pain reliever.The newly app ...

Subin Baral, EY global life sciences deals leader, told GEN M&A deals are expected to increase in 2025, driven by biopharmas that are eager to recoup revenues they expect to lose as their aging ...

NHS England has agreed a deal with Vertex for its three-drug cystic fibrosis therapy Kaftrio, just days after the EMA’s human medicines committee recommended approval of the drug. The deal means ...